Authors (year), Country | Design | Sample Size | Intervention | Study Population Characteristics | Study aim |
---|---|---|---|---|---|
Adler D. (2004), USA [42] | Randomized with 18-months follow-up | 533 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients met DSM-IV criteria for major depressive disorder and/or dysthymia | To examine the clinical pharmacist’s role in the treatment of depression in primary care |
Carter B. (2009), USA [25] | Cluster-randomized with 6-months follow-up | 302 | Medication review, pharmaceutical meeting and recommendations to physicians Measures taking and demand of biological tests | Patients over 21 years of age having a diagnosis of essential hypertension taking 0 to 3 antihypertensive medications without diabetes mellitus | To evaluate if a physician and pharmacist collaborative model in community-based medical offices could improve BP control |
Carter B. (2015), USA [26] | Cluster-randomized with 24-months follow-up | 625 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients with no BP control | To evaluate the pharmacist-physicians collaboration could improve BP control |
Carter B. (2018), USA [27] | Cluster-randomized with 12-months follow-up | 302 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients over 50 years with a history of at least one of the following: diabetes mellitus, hypertension, hypercholesterolemia | To assess whether the pharmacist intervention would be successfully implemented into private family physician offices |
Chen Z. (2013), USA [28] | Cluster-randomized with 6-months follow-up | 374 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients aged 21 to 85 years and were receiving treatment with 0 to 3 antihypertensive agents with no changes to their regimen within the past 4 weeks | To detail the changes in specific antihypertensives associated with the differences in 24-hour BP following a physician-pharmacist co-management |
Finley P. (2002), USA [39] | Randomized with 6-months follow-up | 220 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients suffering from depression and subsequently received prescriptions for antidepressant medication | To evaluate the impact of a collaborative pharmacy practice model on the treatment of depression in primary care |
Finley P. (2003), USA [40] | Randomized with 6-months follow-up | 125 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients who need antidepressant medication | To test the effects of this collaborative care model on drug adherence rates, patient outcomes, provider and patient satisfaction, and medical resource utilization |
Heisler M. (2012), USA [29] | Cluster-randomized with 14-months follow-up | 4100 | Medication review, pharmaceutical meeting and recommendations to physicians Measure of BP and demand of biological tests | Patients with diabetes mellitus had persistent poor BP control and poor refill adherence or insufficient medication intensification | To evaluate if the pharmacist intervention improve BP control |
Hogg W. (2009), Canada [30] | Randomized with 18-months follow-up | 241 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients over 50 years, rostered in the practice, and considered by their family physicians to be good candidates to benefit from additional medical resources and at risk of functional decline, physical deterioration, or experiencing an event requiring emergency services | To evaluate the benefits of home-based multidisciplinary team management involving a nurse practitioner, a pharmacist, and a general practitioner working collaboratively on providing care to community-dwelling patients who were at risk of poor health outcomes |
Jameson J. (2010), USA [31] | Randomized with 12-months follow-up | 104 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients having HbA1c levels of 9.0% or higher or non-office visits within 12 months | To investigate the effect of pharmacist management of poorly controlled diabetes mellitus in a community-based primary care group |
Lenaghan E. (2007), UK [41] | Randomized with 6-months follow-up | 136 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients over 80 years, living in their own homes, who were prescribed at least four oral daily medicines | To study whether a home-based intervention in an at-risk elderly population could reduce hospital admissions |
Omran D. (2015), Canada [32] | Randomized with 6-months follow-up | 260 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients with type 2 diabetes | To determine whether observed improvements in BP resulted from pharmacists’ recommendations to improve antihypertensive medication management or patients’ adherence to antihypertensive medications |
Pape G. (2011), USA [33] | Cluster-randomized with 24-months follow-up | 6963 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients with type 2 diabetes | To evaluate the impact of remote physician-pharmacist team-based care on cholesterol levels in patients with diabetes mellitus |
Sellors J. (2003), Canada [43] | Randomized with 5-months follow-up | 889 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients aged 65 years or more, taking 5 medications | To evaluate pharmacist intervention could reduce daily units of medication taken and improving patient outcomes |
Simpson S. (2011), Canada [34] | Randomized with 12-months follow-up | 260 | Medication review, pharmaceutical meeting and recommendations to physicians Measures taking and demand of biological tests | Patients with type 2 diabetes | To study the effect of adding pharmacists to extant multidisciplinary primary care teams on cardiovascular risk-factor management in type 2 diabetes |
Smith S. (2016), USA [35] | Cluster-randomized with 9-months follow-up | 169 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients without BP control and taking 3 or more antihypertensive medications | To compare a physician-pharmacist collaborative care model to usual hypertension care |
Tahaineh L. (2011), Jordan [36] | Randomized with 6-months follow-up | 159 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients with dyslipidemia | To evaluate the impact of implementing a clinical pharmacy service on achieving lipid profile goals in primary care setting |
Tobari H. (2010), Japan [37] | Randomized with 6-months follow-up | 132 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients 40–79 years of age with hypertension | To evaluate physician-pharmacist cooperation can reduce antihypertensive medication use and cardiovascular risk factors in patient with mild to moderate hypertension by improving BP control |
Weber C. (2010), USA [38] | Cluster-randomized with 9-months follow-up | 179 | Medication review, pharmaceutical meeting and recommendations to physicians | Patients aged 21 to 85 years and were receiving treatment with 0 to 3 antihypertensive agents with no changes to their regimen within the past 4 weeks | To report the results of 24-hour ambulatory BP monitoring obtained during a pharmacist-physician collaborative model of hypertension management |